AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Insight Molecular Diagnostics Inc. Director's Dealing 2021

Apr 30, 2021

34238_dirs_2021-04-30_e1401765-ae22-451a-a530-16cb89700bd0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-04-28

Reporting Person: Levine Mitchell S (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-28	Common Shares, no par value	M	20000	—	Acquired	66700	Direct
2021-04-28	Common Shares, no par value	F	4620	—	Disposed	62080	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-28	Restricted Stock Units	$0	M	20000	Disposed		Common Shares (20000)	Direct

Footnotes

F1: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 20,000 Restricted Stock Units, the grant of which was previously reported on a Form 4.

F2: Restricted Stock Units vested on April 28, 2021.